InsiderTrades

Form 4 for AMGN Amgen

Accepted 2025-02-10 00:00:00 ET · period of report 2025-02-07 · accession 0001127602-25-003984 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-02-10 2025-02-07 AMGN Graham Jonathan P EVP, Gen. Counsel, Secy M - OptEx $156.35 +25.0K 54.0K +86% +$3.92M
D 2025-02-10 2025-02-07 AMGN Graham Jonathan P EVP, Gen. Counsel, Secy S - Sale+OE $293.12 -25.0K 29.0K -46% -$7.34M
D 2025-02-10 2025-02-07 AMGN Graham Jonathan P EVP, Gen. Counsel, Secy M - OptEx $0.00 -25.0K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-02-07 M A 25,045 $156.35 54,032 D — — (F1) These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026.
2 Common Common Stock 2025-02-07 S D 25,045 $293.12 28,987 D — — (F2) The price reported is an average price. Full information regarding the number of shares sold at each separate price is available upon request by the SEC staff, the issuer or a security holder of the issuer. (F3) These shares include 634 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
3 Derivative Nqso (Right to Buy) 2025-02-07 M D 25,045 $0.00 0 D $156.35 · 2018-05-03 to 2026-05-03 25,045 Common Stock